Fierce Pharma1d
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Clinical Trials Arena3d
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial
Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.